WallStSmart

Tilray Inc (TLRY)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1608% more annual revenue ($14.30B vs $837.32M). TLRY leads profitability with a -2.5% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

TLRY

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TLRY1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

TLRY4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.1%4/10

3.1% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$775.94M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-84.1%2/10

ROE of -84.1% — below average capital efficiency

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : TLRY

The strongest argument for TLRY centers on Price/Book.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : TLRY

The primary concerns for TLRY are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

TLRY carries more volatility with a beta of 2.09 — expect wider price swings.

VTRS is growing revenue faster at 5.0% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (50/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Tilray Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Tilray Inc. is dedicated to the research, cultivation, production and distribution of medicinal cannabis and cannabinoids. The company is headquartered in Leamington, Canada.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?